Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,052 total articles
Alibaba is visibly reallocating capital and GMV tailwinds toward building an AI and cloud infrastructure that could reframe its margins and franchise over the next 12 months. The market has punished the stock for cyclical and geopolitical noise, creating a tactical entry for investors who want exposure to China’s leading AI stack builder. Trade pla…
Shake Shack's revenue acceleration and management guidance, combined with analyst upgrades pointing to margin recovery, make the stock a sensible mid-term long. Technicals have caught up to fundamentals and the risk/reward favors a trade targeting a re-rating back toward prior multiples if execution continues.
First Advantage (FA) reported back-to-back quarters of revenue growth and positive free cash flow while integrating Sterling. The stock trades near $10.94 with a market cap of ~$1.9B, EV/EBITDA ~9.8 and price-to-sales ~1.21. We upgrade to Buy on the combination of improving operating performance, healthy free cash flow ($188.5M last reported) and a…
Duos Technologies (DUOT) has delivered outsized revenue growth and is doubling down on an Edge Data Center rollout that could reframe its revenue mix. I remain constructive: the balance sheet has been bolstered via recent offerings, deployment cadence is accelerating, and market appetite for modular edge infrastructure is intact. This is a high-ris…
TSMC capacity pressures are about to get worse as AI demand surges, and Nvidia - the largest consumer of advanced nodes - is best positioned to capture the upside. With a $4.64T market cap, strong free cash flow and commanding profitability, Nvidia offers a balanced risk-reward for a mid-term swing trade that prices in a near-term supply-driven ear…
Dynagas LNG appears to be priced for a worst-case outcome despite a portfolio of long-term charters and predictable cash flow optionality. This trade idea buys the mismatch between visible cash generation and headline market fear - targeting a pragmatic re-rating while capping downside with a strict stop.
Cisco is quietly shifting its product mix toward AI-ready networking, security enforcement and campus refreshes. The stock is carving technical support above its moving averages while fundamentals - $12.24B annual free cash flow, 23% ROE and a manageable 0.63 debt/equity - give the company optionality to buy back stock or accelerate investments. Th…
Nu Holdings is trading below its 50-day average after a sell-off driven by questions about its U.S. strategy. Fundamentals remain intact: 45% revenue growth to $16.3B in 2025, 131M customers, and improving profitability. This trade targets a measured rebound into those fundamentals with a clear stop if credit trends or regulatory setbacks materiali…
Voyager Therapeutics (VYGR) is a clinical-stage gene-therapy company with a deepening Alzheimer’s disease franchise. With compelling preclinical data on its anti-tau antibody VY7523 presented at AD/PD 2025 and a cash runway into mid-2027, the stock offers asymmetric upside if clinical signals materialize in 2026. We rate VYGR a Strong Buy as a trad…
Ramaco Resources (METC) is a metallurgical coal producer trading at roughly $910M market cap. A March 31 reorganization that carved out a Rare Earth and Critical Mineral Development division gives the company optionality to become a rare-earth play. That optionality is real but binary; the shares trade near $13.54 and offer asymmetric upside if Bro…
Guidewire dropped into oversold territory after a sharp retrenchment from last year's highs. Fundamentals still show durable subscription demand, improving cloud momentum and solid free cash flow. This trade idea outlines a long entry at $118 with a $170 target and a $100 stop, keyed to a 180-trading-day horizon and a clear set of catalysts and exi…
Cirrus Aircraft is the rare pure-play exposure to general aviation. Strong product lineup, high-margin services potential, and limited public comparables make it an asymmetric trade. This note lays out a disciplined entry at $18.00, a protective stop at $15.00 and a primary target at $30.00, with variants for shorter and longer holding periods and …
Adobe is trading like a growth company with broken fundamentals — when in reality it remains a high-margin, cash-generative franchise with durable pricing power and a healthy balance sheet. At current levels the stock offers an attractive entry for a long trade with defined risk, multiple near-term catalysts and a realistic path to meaningful upsid…
Uber's platform economics, positive free cash flow, and active partnerships position it to be the demand layer for autonomous vehicle fleets. With the stock trading near $70.60, attractive FCF and profitability metrics give the company optionality to monetize robotaxi services. This trade idea buys that optionality with a disciplined entry, stop an…
Papa John's offers a rare combination: a 5%+ trailing yield, positive free cash flow, and recurring takeover interest. The dividend is attractive but not without caveats; this trade idea targets a mid-term re-rating toward reported bid levels while protecting capital with a tight stop.
Scotts Miracle-Gro (SMG) offers a pragmatic long trade: stable consumer cash flow, a meaningful dividend, progress on debt reduction and a simplification of the business after the Hawthorne divestiture. Valuation metrics (EV/EBITDA ~11.7, P/FCF ~9.8) and a $358M free cash flow run rate underpin a mid-term entry. The trade balances income with a def…
Texas Instruments (TXN) is an analog powerhouse with a defensive customer base, a newly completed Sherman fab coming online and a stretched but defendable valuation. We recommend a mid-term swing trade to capture margin relief and dividend support: entry $215.51, stop $205.00, target $231.32 over 45 trading days.
US Foods is trading like a dependable distributor benefitting from consumer trade-downs and consolidation in foodservice. With $959M in free cash flow, a $20.16B equity value and an EV/EBITDA of 15.0, the business is cash-generative and relatively insulated versus restaurants and consumer discretionary names. We present a mid-term (45 trading days)…
Mastercard (MA) pulled back on recent risk-off flows and dividend timing, creating a clean entry for patient traders. The company still posts high-margin, high-cashflow economics - market cap $444.8B, free cash flow ~$17.2B and ROE north of 190% - while valuation sits at a reasonable multiple for growth at ~29.7x earnings. We upgrade to Buy and rec…
CoreWeave rallied on multi-year deals with Meta and Anthropic and fresh financing; technical momentum and volume suggest a sustainable uptrend. Valuation is rich, execution risk is real, but current price action offers an asymmetric trade when sized and managed properly.
Redwire sells specialized space infrastructure and has accumulated a string of government contracts and analyst optimism that could re-rate the stock. At a $1.78B market cap, improving program mix and a potential margin inflection make RDW a high-risk, high-reward swing trade. Entry $9.00, target $15.00, stop $6.50.
Capital One's transformative moves - notably the Discover deal and Brex tuck-ins - have materially changed the firm's revenue profile but introduced integration execution risk and greater exposure to subprime credit cycles. At $193, the shares look reasonably valued on tangible book and cash flow, but outsized P/E and rising credit noise argue for …
UnitedHealth (UNH) is a battered franchise trading at $304.80 with a $276.3B market cap, 2026 EPS of $13.28 and free cash flow of $16.08B. Recent CMS Medicare Advantage rate tailwinds and Optum-driven efficiency improvements underpin a constructive mid-term trade. I'm advocating a tactical long: entry $305.00, target $360.00, stop $285.00, mid-term…
Credo (CRDO) reported blowout top-line growth and industry-leading margins, but a post-earnings optics-driven pullback and repeated headlines about customer concentration scared momentum traders. That dynamic has left a tradeable entry: buy now with a tight stop under the recent moving-average cluster and a mid-term target that assumes multiple exp…
Ultragenyx plunged after Phase III setbacks for setrusumab and has since priced in meaningful legal and clinical risk. With a market cap around $2.25B, roughly $1.1B in cash on the balance sheet and an enterprise value of $1.87B, the company can fund operations and pivot while the market digests potential settlement outcomes, upcoming corporate upd…
